BioCentury | Nov 18, 2020
Emerging Company Profile

InterVenn: liquid biopsy diagnostics based on glycoproteins

...fibrotic diseases and COVID-19.Genoa Ventures, Amplify Partners, True Ventures...
...employees: 52Funds raised: $44 millionInvestors: Genoa Ventures, True Ventures...
BioCentury | Jan 7, 2020
Financial News

Jan. 7 Financial Quick Takes: Deep Genomics raises $40M; plus Arcutis, Kintor file for IPOs, TwinStrand and RootPath

...round led by Future Ventures, with participation from Amplitude Ventures, Khosla Ventures, Magnetic Ventures and True Ventures...
BioCentury | Oct 25, 2019
Emerging Company Profile

Deep Genomics: Letting AI take the wheel

...California San Diego Corporate partners: N/A Number of employees: 38 Funds raised: $16.7 million Investors: True Ventures...
BioCentury | Aug 2, 2019
Financial News

Aug. 2 Financial Quick Takes: Rakuten Medical bags another $100M; plus CGeneTech, Zecen, Qyuns and more

...capital raised by the company since its founding in 2016 to $10.5 million. Seed investors True Ventures...
BioCentury | Dec 14, 2018
Financial News

Zymergen raises more than $400M in series C

...SoftBank Vision Fund. New investors Goldman Sachs and Hanwha Asset Management joining existing investors DCVC, True Ventures...
BioCentury | Nov 23, 2015
Financial News

Deep Genomics completes venture financing

...Business: Genomics, Bioinformatics Date completed: 2015-11-18 Type: Venture financing Raised: C$5 million ($3.8 million) Investors: True Ventures...
BioCentury | May 28, 2009
Strategy

Fast Forward in MS

Fast Forward LLC , a not-for-profit venture firm spun out of the National Multiple Sclerosis Society in the U.S., has partnered with EMD Serono Inc. to fill the funding gap between preclinical research and drug development...
BioCentury | May 6, 2002
Finance

Ebb & Flow

Biotech advocates can be excused for their increasing frustration. Even as the industry's leaders continue to post profits, the BioCentury 100 lost another 2% last week and fell beneath the 1300 barrier (1295) for the...
BioCentury | Oct 6, 1997
Finance

Hope springs eternal

With a 15 percent run up in the BioCentury 100 in the third quarter, it comes as no surprise that biotech companies are lining up to sell stock. While the window isn't wide open by...
BioCentury | Oct 6, 1997
Company News

Cubist, Novalon deal

The companies extended through February 2001, their May 1997 research collaboration to screen antibacterial and antifungal target proteins and discover inhibitors of these targets using Novalon's Biomolecular Recognition System (see BioCentury, May 12). In the...
Items per page:
1 - 10 of 10
BioCentury | Nov 18, 2020
Emerging Company Profile

InterVenn: liquid biopsy diagnostics based on glycoproteins

...fibrotic diseases and COVID-19.Genoa Ventures, Amplify Partners, True Ventures...
...employees: 52Funds raised: $44 millionInvestors: Genoa Ventures, True Ventures...
BioCentury | Jan 7, 2020
Financial News

Jan. 7 Financial Quick Takes: Deep Genomics raises $40M; plus Arcutis, Kintor file for IPOs, TwinStrand and RootPath

...round led by Future Ventures, with participation from Amplitude Ventures, Khosla Ventures, Magnetic Ventures and True Ventures...
BioCentury | Oct 25, 2019
Emerging Company Profile

Deep Genomics: Letting AI take the wheel

...California San Diego Corporate partners: N/A Number of employees: 38 Funds raised: $16.7 million Investors: True Ventures...
BioCentury | Aug 2, 2019
Financial News

Aug. 2 Financial Quick Takes: Rakuten Medical bags another $100M; plus CGeneTech, Zecen, Qyuns and more

...capital raised by the company since its founding in 2016 to $10.5 million. Seed investors True Ventures...
BioCentury | Dec 14, 2018
Financial News

Zymergen raises more than $400M in series C

...SoftBank Vision Fund. New investors Goldman Sachs and Hanwha Asset Management joining existing investors DCVC, True Ventures...
BioCentury | Nov 23, 2015
Financial News

Deep Genomics completes venture financing

...Business: Genomics, Bioinformatics Date completed: 2015-11-18 Type: Venture financing Raised: C$5 million ($3.8 million) Investors: True Ventures...
BioCentury | May 28, 2009
Strategy

Fast Forward in MS

Fast Forward LLC , a not-for-profit venture firm spun out of the National Multiple Sclerosis Society in the U.S., has partnered with EMD Serono Inc. to fill the funding gap between preclinical research and drug development...
BioCentury | May 6, 2002
Finance

Ebb & Flow

Biotech advocates can be excused for their increasing frustration. Even as the industry's leaders continue to post profits, the BioCentury 100 lost another 2% last week and fell beneath the 1300 barrier (1295) for the...
BioCentury | Oct 6, 1997
Finance

Hope springs eternal

With a 15 percent run up in the BioCentury 100 in the third quarter, it comes as no surprise that biotech companies are lining up to sell stock. While the window isn't wide open by...
BioCentury | Oct 6, 1997
Company News

Cubist, Novalon deal

The companies extended through February 2001, their May 1997 research collaboration to screen antibacterial and antifungal target proteins and discover inhibitors of these targets using Novalon's Biomolecular Recognition System (see BioCentury, May 12). In the...
Items per page:
1 - 10 of 10